By Donato Paolo Mancini
Fresenius Medical Care AG & Co. KGaA (FME.XE) will acquire or has acquired majority stakes in a number of Chinese dialysis companies as it pushes plans to expand in China, the company said Wednesday.
Fresenius will acquire a 70% share in chronic-diseases-services company Guangzhou KangNiDaiSi Medical Investment Co. The company has also acquired 55% stakes in Henan Aishen Hospital Management Co. and Aishen Beijing Hospital Management Co. Both companies are active in the field of dialysis. They cover the Henan, Shandong, Guangdong and Hainan provinces, Fresenius said, with plans to expand in the future.
Fresenius has also taken a 60% share in Daqing Kangda Dialysis Center Co. in Heilongjiang.
Chronic kidney disease has a 10.8% prevalence in China, said Fresenius.
Write to Donato Paolo Mancini at firstname.lastname@example.org; @donatopmancini